PL352741A1 - Leczenie migreny przez podawanie kwasu alfa-lioponowego lub jego pochodnych - Google Patents

Leczenie migreny przez podawanie kwasu alfa-lioponowego lub jego pochodnych

Info

Publication number
PL352741A1
PL352741A1 PL00352741A PL35274100A PL352741A1 PL 352741 A1 PL352741 A1 PL 352741A1 PL 00352741 A PL00352741 A PL 00352741A PL 35274100 A PL35274100 A PL 35274100A PL 352741 A1 PL352741 A1 PL 352741A1
Authority
PL
Poland
Prior art keywords
migraine
lipoic acid
alpha
treatment
administration
Prior art date
Application number
PL00352741A
Other languages
English (en)
Other versions
PL200928B1 (pl
Inventor
Jean Schoenen
Jurgen Engel
Klaus Wessel
Manfred Peukert
Michael Lobisch
Harald Borbe
Original Assignee
VIATRIS Gmbh & Co.KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VIATRIS Gmbh & Co.KG filed Critical VIATRIS Gmbh & Co.KG
Publication of PL352741A1 publication Critical patent/PL352741A1/pl
Publication of PL200928B1 publication Critical patent/PL200928B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL352741A 1999-08-30 2000-08-26 Zastosowanie kwasu α-liponowego lub jego pochodnych do wytwarzania leku do zapobiegania albo leczenia migreny PL200928B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19941217A DE19941217A1 (de) 1999-08-30 1999-08-30 Behandlung der Migräne durch Verabreichung von alpha-Liponsäure oder Derivaten derselben
PCT/EP2000/008315 WO2001015693A2 (de) 1999-08-30 2000-08-26 BEHANDLUNG DER MIGRÄNE DURCH VERABREICHUNG VON α-LIPONSÄURE ODER DERIVATEN DERSELBEN

Publications (2)

Publication Number Publication Date
PL352741A1 true PL352741A1 (pl) 2003-09-08
PL200928B1 PL200928B1 (pl) 2009-02-27

Family

ID=7920152

Family Applications (1)

Application Number Title Priority Date Filing Date
PL352741A PL200928B1 (pl) 1999-08-30 2000-08-26 Zastosowanie kwasu α-liponowego lub jego pochodnych do wytwarzania leku do zapobiegania albo leczenia migreny

Country Status (31)

Country Link
US (1) US6251935B1 (pl)
EP (1) EP1207878B1 (pl)
JP (1) JP4773015B2 (pl)
KR (1) KR100624215B1 (pl)
CN (1) CN1170535C (pl)
AT (1) ATE232725T1 (pl)
AU (1) AU781505B2 (pl)
BG (1) BG65735B1 (pl)
BR (1) BR0013651A (pl)
CA (1) CA2382548C (pl)
CZ (1) CZ301789B6 (pl)
DE (2) DE19941217A1 (pl)
DK (1) DK1207878T3 (pl)
EE (1) EE04869B1 (pl)
ES (1) ES2190985T3 (pl)
HR (1) HRP20020168A2 (pl)
HU (1) HU229603B1 (pl)
IL (2) IL148068A0 (pl)
IS (1) IS2214B (pl)
MX (1) MXPA02002246A (pl)
NO (1) NO328692B1 (pl)
NZ (1) NZ517276A (pl)
PL (1) PL200928B1 (pl)
PT (1) PT1207878E (pl)
RS (1) RS50139B (pl)
RU (1) RU2232577C2 (pl)
SK (1) SK286260B6 (pl)
TR (1) TR200200461T2 (pl)
UA (1) UA71031C2 (pl)
WO (1) WO2001015693A2 (pl)
ZA (1) ZA200201637B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2352144A1 (en) * 1998-11-25 2000-06-02 Yissum Research Development Company Of The Hebrew University In Jerusale M Scavenger compounds
US7030154B2 (en) 2002-06-07 2006-04-18 Juvenon, Inc. Stability of lipoic acid
US20050065094A1 (en) 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
US20090054513A1 (en) * 2007-08-22 2009-02-26 Response Scientific, Inc. Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
US7943163B2 (en) * 2007-08-22 2011-05-17 Response Scientific, Inc. Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes
RU2424803C2 (ru) * 2008-04-07 2011-07-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН (НИИ фармакологии имени В.В.Закусова РАМН) Фармацевтическая композиция с противомигреневым действием (варианты)
ES2529060T3 (es) 2008-11-24 2015-02-16 Cedars-Sinai Medical Center Derivados antioxidantes de la camptotecina y nanoesferas antineoplásicas antioxidantes de los mismos
AU2010247141A1 (en) 2009-05-15 2011-12-15 Redx Pharma Plc Redox drug derivatives
KR100935554B1 (ko) 2009-06-24 2010-01-07 주식회사 셀트리온제약 피페라진 다이티옥트산염 및 이를 포함하는 약제학적 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU620265A1 (ru) * 1977-02-21 1978-08-25 Центральный Ордена Трудового Красного Знамени Научно-Исследовательский Институт Курортологии И Физиотерапии Способ лечени атеросклероза сосудов головного мозга и гипертонической болезни
ES2043897T3 (es) * 1988-01-28 1994-01-01 Koeltringer Peter Preparado de combinacion, en especial para el tratamiento de enfermedades de las celulas nerviosas.
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
EP0812590A3 (de) * 1989-11-09 1999-06-09 ASTA Medica Aktiengesellschaft Verwendung von R-Alpha-Liponsäure zur Zytoprotektion
DE4218572A1 (de) * 1992-06-05 1993-12-09 Asta Medica Ag Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
US5569670A (en) * 1992-06-05 1996-10-29 Asta Medica Aktiengesellschaft Combination medications containing alpha-lipoic acid and related
DE69331727D1 (de) * 1992-06-30 2002-04-25 Howard K Shapiro Verwendung einer kombination bestehend aus einem aminderivat oder aminverwandten derivat der benzoesäure und einem amino-polysaccharide zur herstellung eines medikaments fuer die behandlung von entzündlichen erkrankungen
DE4327426A1 (de) * 1993-08-14 1995-02-16 F H Erdaussiebung Gmbh Anbaugerät zum Sieben und Verfüllen von Erdmaterialien
DE4327462A1 (de) * 1993-08-16 1995-02-23 Carl Heinrich Dr Weischer Neue N-Acetyl-p-Aminophenol-Derivate zur Bekämpfung von Schmerzzuständen
DE4331168A1 (de) * 1993-09-14 1995-03-16 Carl Heinrich Dr Weischer Kombination von N-Acetyl-p-Aminophenol mit schwefelenthaltenden Carbonsäuren, wie z. B. alpha-Liponsäure und deren Derivate, zur Bekämpfung von Schmerzzuständen
EP0855396A1 (en) * 1997-01-22 1998-07-29 ASTA Medica Aktiengesellschaft Thioctic acid metabolites and methods of use thereof
IL123887A0 (en) * 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
AU8768098A (en) * 1997-08-04 1999-02-22 Christopher J. Berry Method of treating disease using a tocotrienol and alpha-lipoic acid r derivatives or an ester thereof
GB2333757B (en) * 1998-02-03 2001-06-27 Cheung Kwok Chung Sliding platform
WO1999051097A1 (en) * 1998-04-02 1999-10-14 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent
AR042572A1 (es) * 1999-04-02 2005-06-29 Sod Conseils Rech Applic Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos

Also Published As

Publication number Publication date
IS2214B (is) 2007-03-15
CN1371280A (zh) 2002-09-25
BR0013651A (pt) 2002-05-07
HUP0203025A2 (hu) 2002-12-28
DE50001301D1 (de) 2003-03-27
PT1207878E (pt) 2003-07-31
MXPA02002246A (es) 2003-08-20
CA2382548A1 (en) 2001-03-08
CZ2002655A3 (cs) 2002-07-17
JP4773015B2 (ja) 2011-09-14
SK2902002A3 (en) 2002-09-10
ATE232725T1 (de) 2003-03-15
NZ517276A (en) 2004-06-25
NO328692B1 (no) 2010-04-26
YU15002A (sh) 2005-03-15
HUP0203025A3 (en) 2004-12-28
HRP20020168A2 (en) 2003-06-30
WO2001015693A3 (de) 2001-12-20
ES2190985T3 (es) 2003-09-01
IL148068A (en) 2007-06-03
ZA200201637B (en) 2003-01-29
CA2382548C (en) 2007-07-03
AU781505B2 (en) 2005-05-26
NO20020917D0 (no) 2002-02-25
US6251935B1 (en) 2001-06-26
UA71031C2 (uk) 2004-11-15
BG65735B1 (bg) 2009-09-30
CN1170535C (zh) 2004-10-13
IS6284A (is) 2002-02-26
EE200200098A (et) 2003-04-15
EP1207878A2 (de) 2002-05-29
IL148068A0 (en) 2002-09-12
HU229603B1 (en) 2014-02-28
EP1207878B1 (de) 2003-02-19
TR200200461T2 (tr) 2002-08-21
CZ301789B6 (cs) 2010-06-23
DE19941217A1 (de) 2001-03-15
BG106407A (en) 2002-10-31
EE04869B1 (et) 2007-08-15
HK1046637A1 (en) 2003-01-24
JP2003508438A (ja) 2003-03-04
PL200928B1 (pl) 2009-02-27
WO2001015693A2 (de) 2001-03-08
NO20020917L (no) 2002-02-25
SK286260B6 (sk) 2008-06-06
DK1207878T3 (da) 2003-06-16
RU2232577C2 (ru) 2004-07-20
KR100624215B1 (ko) 2006-09-18
KR20020060168A (ko) 2002-07-16
RS50139B (sr) 2009-03-25
AU7279900A (en) 2001-03-26

Similar Documents

Publication Publication Date Title
MY130441A (en) Solutions containing epinastin
PL350456A1 (en) N−cyanomethylamides as protease inhibitors
WO2001027111A3 (de) Bicyclische imidazo-3-yl-aminderivate
MXPA05002871A (es) Derivados de benzodiazaepina y composiciones farmaceuticas que los contienen.
IL149337A0 (en) Phenoxy carboxylic acid compounds and compositions for delivering active agents
CA2445145A1 (en) Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
CY1110664T1 (el) Ενδορινικες συνθεσετς
IL148068A0 (en) TREATMENT OF MIGRAINE BY ADMINISTRATION OF α-LUPOIC ACID OR DERIVATIVES THEREOF
MXPA02012182A (es) Medicamentos para la terapia de demencias.
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
MXPA05008711A (es) Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
WO2002009717A1 (en) Erectile dysfunction remedies containing prostaglandin derivatives as the active ingredient
EP1219296A4 (en) SEBUM PRODUCTION INHIBITORS
AR026435A1 (es) Procedimiento para la administracion simplificada del acido alfa-lipoico, o de derivados del mismo y el procedimiento para preparar la composicionfarmaceutica o nutricional de aplicacion en dicho metodo
SI1207878T1 (en) Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof
EP1452522A3 (en) Novel compounds and compositions as protease inhibitors
WO2000003699A3 (de) Arzneimittel mit einem gehalt an phosphonsäurederivaten als wirkstoff und ihre verwendung
EP1106177A4 (en) AGENTS FOR INCREASING MEDICINE ACCUMULATION IN TUMOR TISSUES